Sequent Scientific Ltd
Add to watch list to get report alerts
BSE Code:
512529
NSE Code:
SEQUENT
Business Profile
Business Profile
PI Drugs and Pharmaceuticals (VISTRAFI), established in 1991, is engaged in the business of human and animal health. The company manufactures bulk drugs, oral powders, oral suspensions, API, granules, albendazole. The product list of the company includes Toldimfos Sodium, Quinapyramine, Diminazene Diaceturate, Niclosamide, Flubendazole, Clorsulon USP, ..etc. It is one of the largest producers of Albendazole in the country. It has also commissioned the liquid line at Additional Ambernath. The company`s plants are located at Tarapur, Raigad and Ambernath in Maharashtra and its research and development centers are located in Bangalore and Kumta. The total installed capacity of the company is 150 MT per annum.The company exports to all major markets like Europe, South America, Australia, Asia and Africa.
Financials
PI Drugs and Pharmaceuticals posted a net profit of Rs 76.7 million for the year ended Mar. 31, 2007 on an operating income of Rs 369.71 million. Total income for the year stood at Rs 401 million. During the year, the company posted an EPS of Rs 7.26.
Recent Developments
09-JUL-07
On July 9, 2007, the board of directors allotted 2,785,188 equity shares of Rs 10/- each at a premium of Rs 55/- each aggregating to Rs 181,037,220/- to Fraxis Life Sciences on preferential basis after getting consent from shareholders.
20-APR-06
The board of directors at its meeting held on April 20, 2006 has considered and decided to acquire 100% equity of Elixir Chemicals, an unlisted company engaged in pharma business, for consideration of Rs 70 million on cash basis.